From ADA 2018: Two new biomarkers predict CV events independently of conventional risk factors, plus post-hoc analysis of VADT.
Kenneth J. Bender, PharmD, MA
Severe hypoglycemia is more prevalent than previously believed and also significantly underreported. Details from 3 studies at ADA 2018.
Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
What is the impact on insulin dose, A1c, body weight of adding GLP-1 RA to a MDI insulin regimen? Three studies from ADA 2018 illuminate.
Should you: Stop a DPP-4i when you start insulin? Prescribe initial triple combination Rx? What about SGLT2i + DPP-4i + MET vs insulin + MET? Find out.
How do 2nd generation basal insulin formulations perform vs their predecessors? We report highlights of 3 important studies from the ADA 78th Scientific Sessions.
Terms such as "opioid McCarthyism" and "witch hunt" were used to express frustration with current opioid regulatory efforts.
From PAINWeek 2017: Reflex vasodilation is out, neurobiologic dysfunction is in as explanation for migraine etiology.
An early session at PAINWeek 2017 addressed prescriber fear as regulatory agencies "pile on" across overlapping jurisdictions.
Studies summarized in this slide show focus on fine-tuning insulin-containing regimens to enhance glucose control and avoid variability.